Biogen, an American multinational biotechnology company, completed the acquisition of a 17.15% stake in Sangamo Therapeutics, an American biotechnology company based in Brisbane, California, for $350m. "There are currently no approved disease modifying treatments for patients with many devastating neurodegenerative diseases such as Alzheimer’s and Parkinson’s, creating an urgency for the development of medicines that will not just address symptoms like the current standards of care, but slow or stop the progression of disease. We believe that the promise of genomic medicine in neuroscience is to provide a one-time treatment for patients to alter their disease natural history by addressing the underlying cause at the genomic level," Sandy Macrae, Sangamo CEO.